Industry Research Reports
Home > Reports > Service & Software > Global Canine Tumor Screening Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Canine Tumor Screening Market Outlook, In‑Depth Analysis & Forecast to 2032
Industry: Service & Software
Published Date: 2026-03-25
Pages: 120 Pages
Report ld: 6289221
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Canine Tumor Screening Market Size(US$)
CAGR 2026-2032
6.5%
Market Size,2032
USD 672
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 460 million
Market Forecast in 2032(Value)
US$ 672 million
CAGR
6.5%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Canine Tumor Screening market is projected to grow from US$ 435 million in 2025 to US$ 672 million by 2032, at a CAGR of 6.5% (2026-2032), driven by critical product segments and diverse end‑use applications.
Canine liquid biopsy is a method of analyzing biomarkers in body fluids (such as blood, urine or saliva) to detect the presence of cancer or monitor the progression of cancer. Unlike traditional tissue biopsies, liquid biopsies are non-invasive, fast and convenient. By obtaining a small blood sample, doctors can analyze free DNA, circulating tumor cells, exosomes, etc. to obtain information about the tumor.
From a downstream perspective, Pet Hospital accounted for % of 2025 revenue, surging to US$ million by 2032 (CAGR: % from 2026–2032).
Canine Tumor Screening leading players (including PetDx, CYTOGEN, BioChain, Small Door, ANGLE, BioChain Institute Inc., CANCAN DIAGNOSTICS., etc.), dominate supply; the top five capture approximately % of global revenue, with PetDx leading 2025 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2025 to a forecast US$ million by 2032 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2025, % share rising to % by 2032), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2032 (CAGR %).
Report Includes:
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Canine Tumor Screening market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- PetDx
- CYTOGEN
- BioChain
- Small Door
- ANGLE
- BioChain Institute Inc.
- CANCAN DIAGNOSTICS.
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Cut Biopsy
- Needle Biopsy
Segment by Application
- Pet Hospital
- Clinic
CHAPTER OUTLINE
Chapter 1: Defines the Canine Tumor Screening study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Canine Tumor Screening: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Canine Tumor Screening Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Cut Biopsy
1.2.3 Needle Biopsy
1.3 Market Segmentation by Application
1.3.1 Global Canine Tumor Screening Market Size by Application, 2021 vs 2025 vs 2032
1.3.2 Pet Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Canine Tumor Screening Revenue Estimates and Forecasts (2021-2032)
2.2 Global Canine Tumor Screening Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competitive Landscape
3.1 Global Canine Tumor Screening Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Canine Tumor Screening Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Cut Biopsy: Market Share by Key Players
3.3.2 Needle Biopsy: Market Share by Key Players
3.4 Global Canine Tumor Screening Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Product Segmentation
4.1 Global Canine Tumor Screening Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Downstream Applications and Customers
5.1 Global Canine Tumor Screening Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Canine Tumor Screening Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Canine Tumor Screening Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico
7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Canine Tumor Screening Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Canine Tumor Screening Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Canine Tumor Screening Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Canine Tumor Screening Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Canine Tumor Screening Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Canine Tumor Screening Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Canine Tumor Screening Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Canine Tumor Screening Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa
11 Corporate Profile
11.1 PetDx
11.1.1 PetDx Corporation Information
11.1.2 PetDx Business Overview
11.1.3 PetDx Canine Tumor Screening Product Features and Attributes
11.1.4 PetDx Canine Tumor Screening Revenue and Gross Margin (2021-2026)
11.1.5 PetDx Canine Tumor Screening Revenue by Product in 2025
11.1.6 PetDx Canine Tumor Screening Revenue by Application in 2025
11.1.7 PetDx Canine Tumor Screening Revenue by Geographic Area in 2025
11.1.8 PetDx Canine Tumor Screening SWOT Analysis
11.1.9 PetDx Recent Developments
11.2 CYTOGEN
11.2.1 CYTOGEN Corporation Information
11.2.2 CYTOGEN Business Overview
11.2.3 CYTOGEN Canine Tumor Screening Product Features and Attributes
11.2.4 CYTOGEN Canine Tumor Screening Revenue and Gross Margin (2021-2026)
11.2.5 CYTOGEN Canine Tumor Screening Revenue by Product in 2025
11.2.6 CYTOGEN Canine Tumor Screening Revenue by Application in 2025
11.2.7 CYTOGEN Canine Tumor Screening Revenue by Geographic Area in 2025
11.2.8 CYTOGEN Canine Tumor Screening SWOT Analysis
11.2.9 CYTOGEN Recent Developments
11.3 BioChain
11.3.1 BioChain Corporation Information
11.3.2 BioChain Business Overview
11.3.3 BioChain Canine Tumor Screening Product Features and Attributes
11.3.4 BioChain Canine Tumor Screening Revenue and Gross Margin (2021-2026)
11.3.5 BioChain Canine Tumor Screening Revenue by Product in 2025
11.3.6 BioChain Canine Tumor Screening Revenue by Application in 2025
11.3.7 BioChain Canine Tumor Screening Revenue by Geographic Area in 2025
11.3.8 BioChain Canine Tumor Screening SWOT Analysis
11.3.9 BioChain Recent Developments
11.4 Small Door
11.4.1 Small Door Corporation Information
11.4.2 Small Door Business Overview
11.4.3 Small Door Canine Tumor Screening Product Features and Attributes
11.4.4 Small Door Canine Tumor Screening Revenue and Gross Margin (2021-2026)
11.4.5 Small Door Canine Tumor Screening Revenue by Product in 2025
11.4.6 Small Door Canine Tumor Screening Revenue by Application in 2025
11.4.7 Small Door Canine Tumor Screening Revenue by Geographic Area in 2025
11.4.8 Small Door Canine Tumor Screening SWOT Analysis
11.4.9 Small Door Recent Developments
11.5 ANGLE
11.5.1 ANGLE Corporation Information
11.5.2 ANGLE Business Overview
11.5.3 ANGLE Canine Tumor Screening Product Features and Attributes
11.5.4 ANGLE Canine Tumor Screening Revenue and Gross Margin (2021-2026)
11.5.5 ANGLE Canine Tumor Screening Revenue by Product in 2025
11.5.6 ANGLE Canine Tumor Screening Revenue by Application in 2025
11.5.7 ANGLE Canine Tumor Screening Revenue by Geographic Area in 2025
11.5.8 ANGLE Canine Tumor Screening SWOT Analysis
11.5.9 ANGLE Recent Developments
11.6 BioChain Institute Inc.
11.6.1 BioChain Institute Inc. Corporation Information
11.6.2 BioChain Institute Inc. Business Overview
11.6.3 BioChain Institute Inc. Canine Tumor Screening Product Features and Attributes
11.6.4 BioChain Institute Inc. Canine Tumor Screening Revenue and Gross Margin (2021-2026)
11.6.5 BioChain Institute Inc. Recent Developments
11.7 CANCAN DIAGNOSTICS.
11.7.1 CANCAN DIAGNOSTICS. Corporation Information
11.7.2 CANCAN DIAGNOSTICS. Business Overview
11.7.3 CANCAN DIAGNOSTICS. Canine Tumor Screening Product Features and Attributes
11.7.4 CANCAN DIAGNOSTICS. Canine Tumor Screening Revenue and Gross Margin (2021-2026)
11.7.5 CANCAN DIAGNOSTICS. Recent Developments
12 Canine Tumor Screening Value Chain and Ecosystem Analysis
12.1 Canine Tumor Screening Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Canine Tumor Screening Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Canine Tumor Screening Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Canine Tumor Screening Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Canine Tumor Screening Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Canine Tumor Screening Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Canine Tumor Screening Revenue by Region (US$ Million), 2021-2026
Table 5. Global Canine Tumor Screening Revenue by Region (US$ Million), 2027-2032
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 7. Global Canine Tumor Screening Revenue by Players (US$ Million), 2021-2026
Table 8. Global Canine Tumor Screening Revenue-Based Market Share by Players (2021-2026)
Table 9. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 10. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Canine Tumor Screening Revenue, 2025
Table 11. Global Canine Tumor Screening Average Gross Margin (%) by Player (2021 vs 2025)
Table 12. Global Canine Tumor Screening Companies Headquarters
Table 13. Global Canine Tumor Screening Market Concentration Ratio (CR5)
Table 14. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Canine Tumor Screening Revenue by Type (US$ Million), 2021-2026
Table 17. Global Canine Tumor Screening Revenue by Type (US$ Million), 2027-2032
Table 18. Key Product Attributes and Differentiation
Table 19. Global Canine Tumor Screening Revenue by Application (US$ Million), 2021-2026
Table 20. Global Canine Tumor Screening Revenue by Application (US$ Million), 2027-2032
Table 21. Canine Tumor Screening High-Growth Sectors Demand CAGR (2026-2032)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Canine Tumor Screening Growth Accelerators and Market Barriers
Table 25. North America Canine Tumor Screening Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 26. Europe Canine Tumor Screening Growth Accelerators and Market Barriers
Table 27. Europe Canine Tumor Screening Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. Asia-Pacific Canine Tumor Screening Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Canine Tumor Screening Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 30. Central and South America Canine Tumor Screening Investment Opportunities and Key Challenges
Table 31. Central and South America Canine Tumor Screening Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Middle East and Africa Canine Tumor Screening Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Canine Tumor Screening Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 34. PetDx Corporation Information
Table 35. PetDx Description and Major Businesses
Table 36. PetDx Product Features and Attributes
Table 37. PetDx Revenue (US$ Million) and Gross Margin (2021-2026)
Table 38. PetDx Revenue Proportion by Product in 2025
Table 39. PetDx Revenue Proportion by Application in 2025
Table 40. PetDx Revenue Proportion by Geographic Area in 2025
Table 41. PetDx Canine Tumor Screening SWOT Analysis
Table 42. PetDx Recent Developments
Table 43. CYTOGEN Corporation Information
Table 44. CYTOGEN Description and Major Businesses
Table 45. CYTOGEN Product Features and Attributes
Table 46. CYTOGEN Revenue (US$ Million) and Gross Margin (2021-2026)
Table 47. CYTOGEN Revenue Proportion by Product in 2025
Table 48. CYTOGEN Revenue Proportion by Application in 2025
Table 49. CYTOGEN Revenue Proportion by Geographic Area in 2025
Table 50. CYTOGEN Canine Tumor Screening SWOT Analysis
Table 51. CYTOGEN Recent Developments
Table 52. BioChain Corporation Information
Table 53. BioChain Description and Major Businesses
Table 54. BioChain Product Features and Attributes
Table 55. BioChain Revenue (US$ Million) and Gross Margin (2021-2026)
Table 56. BioChain Revenue Proportion by Product in 2025
Table 57. BioChain Revenue Proportion by Application in 2025
Table 58. BioChain Revenue Proportion by Geographic Area in 2025
Table 59. BioChain Canine Tumor Screening SWOT Analysis
Table 60. BioChain Recent Developments
Table 61. Small Door Corporation Information
Table 62. Small Door Description and Major Businesses
Table 63. Small Door Product Features and Attributes
Table 64. Small Door Revenue (US$ Million) and Gross Margin (2021-2026)
Table 65. Small Door Revenue Proportion by Product in 2025
Table 66. Small Door Revenue Proportion by Application in 2025
Table 67. Small Door Revenue Proportion by Geographic Area in 2025
Table 68. Small Door Canine Tumor Screening SWOT Analysis
Table 69. Small Door Recent Developments
Table 70. ANGLE Corporation Information
Table 71. ANGLE Description and Major Businesses
Table 72. ANGLE Product Features and Attributes
Table 73. ANGLE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 74. ANGLE Revenue Proportion by Product in 2025
Table 75. ANGLE Revenue Proportion by Application in 2025
Table 76. ANGLE Revenue Proportion by Geographic Area in 2025
Table 77. ANGLE Canine Tumor Screening SWOT Analysis
Table 78. ANGLE Recent Developments
Table 79. BioChain Institute Inc. Corporation Information
Table 80. BioChain Institute Inc. Description and Major Businesses
Table 81. BioChain Institute Inc. Product Features and Attributes
Table 82. BioChain Institute Inc. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. BioChain Institute Inc. Recent Developments
Table 84. CANCAN DIAGNOSTICS. Corporation Information
Table 85. CANCAN DIAGNOSTICS. Description and Major Businesses
Table 86. CANCAN DIAGNOSTICS. Product Features and Attributes
Table 87. CANCAN DIAGNOSTICS. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. CANCAN DIAGNOSTICS. Recent Developments
Table 89. Technologies, Platforms and Infrastructure
Table 90. Distributors List
Table 91. Market Trends and Market Evolution
Table 92. Market Drivers and Opportunities
Table 93. Market Challenges, Risks, and Restraints
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Canine Tumor Screening Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Cut Biopsy Product Picture
Figure 3. Needle Biopsy Product Picture
Figure 4. Global Canine Tumor Screening Market Size Growth Rate , 2021 vs 2025 vs 2032 (US$ Million)
Figure 5. Global Canine Tumor Screening Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Pet Hospital
Figure 7. Clinic
Figure 8. Canine Tumor Screening Report Years Considered
Figure 9. Global Canine Tumor Screening Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 10. Global Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 11. Global Canine Tumor Screening Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Global Canine Tumor Screening Revenue-Based Market Share by Region (2021-2032)
Figure 13. Global Canine Tumor Screening Revenue-Based Market Share Ranking (2025)
Figure 14. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 15. Cut Biopsy Revenue-Based Market Share by Player in 2025
Figure 16. Needle Biopsy Revenue-Based Market Share by Player in 2025
Figure 17. Global Canine Tumor Screening Revenue-Based Market Share by Type (2021-2032)
Figure 18. Global Canine Tumor Screening Revenue-Based Market Share by Application (2021-2032)
Figure 19. North America Canine Tumor Screening Revenue YoY (US$ Million), 2021-2032
Figure 20. North America Top 5 Players Canine Tumor Screening Revenue (US$ Million) in 2025
Figure 21. North America Canine Tumor Screening Revenue (US$ Million) by Application (2021-2032)
Figure 22. US Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 23. Canada Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 24. Mexico Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 25. Europe Canine Tumor Screening Revenue YoY (US$ Million), 2021-2032
Figure 26. Europe Top 5 Players Canine Tumor Screening Revenue (US$ Million) in 2025
Figure 27. Europe Canine Tumor Screening Revenue (US$ Million) by Application (2021-2032)
Figure 28. Germany Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 29. France Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 30. U.K. Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 31. Italy Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 32. Russia Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 33. Asia-Pacific Canine Tumor Screening Revenue YoY (US$ Million), 2021-2032
Figure 34. Asia-Pacific Top 8 Players Canine Tumor Screening Revenue (US$ Million) in 2025
Figure 35. Asia-Pacific Canine Tumor Screening Revenue (US$ Million) by Application (2021-2032)
Figure 36. Indonesia Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 37. Japan Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 38. South Korea Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 39. Australia Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 40. India Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 41. Indonesia Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 42. Vietnam Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 43. Malaysia Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 44. Philippines Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 45. Singapore Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 46. Central and South America Canine Tumor Screening Revenue YoY (US$ Million), 2021-2032
Figure 47. Central and South America Top 5 Players Canine Tumor Screening Revenue (US$ Million) in 2025
Figure 48. Central and South America Canine Tumor Screening Revenue (US$ Million) by Application (2021-2032)
Figure 49. Brazil Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 50. Argentina Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 51. Middle East and Africa Canine Tumor Screening Revenue YoY (US$ Million), 2021-2032
Figure 52. Middle East and Africa Top 5 Players Canine Tumor Screening Revenue (US$ Million) in 2025
Figure 53. Middle East and Africa Canine Tumor Screening Revenue (US$ Million) by Application (2021-2032)
Figure 54. GCC Countries Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 55. Israel Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 56. Egypt Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 57. South Africa Canine Tumor Screening Revenue (US$ Million), 2021-2032
Figure 58. Canine Tumor Screening Value Chain Mapping
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What is the annual compound growth rate of the global Canine Tumor Screening market size from 2026 to 2032?
The annual compound growth rate of the global Canine Tumor Screening market is 6.5% 2026 to 2032.
Which region is expected to have the highest market share?
What was the global market size of Canine Tumor Screening in 2032?
What was the global market size of Canine Tumor Screening in 2026?
Which companies rank high in the global Canine Tumor Screening market?
Related Reports
Global Canine Tumor Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Canine Tumor Screening market size was US$ 435 million in 2025 and is forecast to reach a readjusted size of US$ 672 million by 2032 with a CAGR of 6.5% during the forecast period 2026-2032.
Published Date: 2026-03-25
Pages: 80
USD 4250.00
(Single User License)
Global Canine Tumor Screening Market Research Report 2026
The global Canine Tumor Screening market was valued at US$ 435 million in 2025 and is anticipated to reach US$ 672 million by 2032, at a CAGR of 6.5% from 2026 to 2032.
Published Date: 2026-01-08
Pages: 104
USD 2900.00
(Single User License)
Canine Tumor Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Canine Tumor Screening was estimated to be worth US$ 435 million in 2025 and is projected to reach US$ 672 million, growing at a CAGR of 6.5% from 2026 to 2032.
Published Date: 2026-01-08
Pages: 97
USD 3950.00
(Single User License)
Global Canine Tumor Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Canine Tumor Screening market size was US$ 411 million in 2024 and is forecast to a readjusted size of US$ 635 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 80
USD 4250.00
(Single User License)
Global Canine Tumor Screening Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Canine Tumor Screening market is projected to grow from US$ 411 million in 2024 to US$ 635 million by 2031, at a CAGR of 6.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-08-01
Pages: 127
USD 4900.00
(Single User License)
Canine Tumor Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Canine Tumor Screening was estimated to be worth US$ 411 million in 2024 and is forecast to a readjusted size of US$ 635 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Published Date: 2025-03-12
Pages: 97
USD 3950.00
(Single User License)
Global Canine Tumor Screening Market Research Report 2025
The global market for Canine Tumor Screening was valued at US$ 411 million in the year 2024 and is projected to reach a revised size of US$ 635 million by 2031, growing at a CAGR of 6.5% during the forecast period.
Published Date: 2025-03-12
Pages: 72
USD 2900.00
(Single User License)
Global and Japan Canine Tumor Screening Market Report & Forecast 2024-2030
The global Canine Tumor Screening revenue was US$ 397 million in 2023 and is forecast to a readjusted size of US$ 600 million by 2030 with a CAGR of 6.5% during the review period (2024-2030).
Published Date: 2024-12-12
Pages: 93
USD 4350.00
(Single User License)
Canine Tumor Screening- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Canine Tumor Screening was estimated to be worth US$ 397 million in 2023 and is forecast to a readjusted size of US$ 600 million by 2030 with a CAGR of 6.5% during the forecast period 2024-2030.
Published Date: 2024-12-12
Pages: 96
USD 3950.00
(Single User License)
Global Canine Tumor Screening Market Insights, Forecast to 2030
Valued at US$ 411 million in 2024, the global Canine Tumor Screening market is forecast to reach US$ 600 million by 2030, at a CAGR of 6.5% during the forecast period.
Published Date: 2024-12-12
Pages: 128
USD 4900.00
(Single User License)
Global Canine Tumor Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Canine Tumor Screening market size was US$ 435 million in 2025 and is forecast to reach a readjusted size of US$ 672 million by 2032 with a CAGR of 6.5% during the forecast period 2026-2032.
Published: 2026-03-25
Pages: 80
USD 4250.00 (Single User License)Global Canine Tumor Screening Market Research Report 2026
The global Canine Tumor Screening market was valued at US$ 435 million in 2025 and is anticipated to reach US$ 672 million by 2032, at a CAGR of 6.5% from 2026 to 2032.
Published: 2026-01-08
Pages: 104
USD 2900.00 (Single User License)Canine Tumor Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Canine Tumor Screening was estimated to be worth US$ 435 million in 2025 and is projected to reach US$ 672 million, growing at a CAGR of 6.5% from 2026 to 2032.
Published: 2026-01-08
Pages: 97
USD 3950.00 (Single User License)Global Canine Tumor Screening Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Canine Tumor Screening market size was US$ 411 million in 2024 and is forecast to a readjusted size of US$ 635 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 80
USD 4250.00 (Single User License)Global Canine Tumor Screening Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Canine Tumor Screening market is projected to grow from US$ 411 million in 2024 to US$ 635 million by 2031, at a CAGR of 6.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-08-01
Pages: 127
USD 4900.00 (Single User License)Canine Tumor Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Canine Tumor Screening was estimated to be worth US$ 411 million in 2024 and is forecast to a readjusted size of US$ 635 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Published: 2025-03-12
Pages: 97
USD 3950.00 (Single User License)Global Canine Tumor Screening Market Research Report 2025
The global market for Canine Tumor Screening was valued at US$ 411 million in the year 2024 and is projected to reach a revised size of US$ 635 million by 2031, growing at a CAGR of 6.5% during the forecast period.
Published: 2025-03-12
Pages: 72
USD 2900.00 (Single User License)Global and Japan Canine Tumor Screening Market Report & Forecast 2024-2030
The global Canine Tumor Screening revenue was US$ 397 million in 2023 and is forecast to a readjusted size of US$ 600 million by 2030 with a CAGR of 6.5% during the review period (2024-2030).
Published: 2024-12-12
Pages: 93
USD 4350.00 (Single User License)Canine Tumor Screening- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Canine Tumor Screening was estimated to be worth US$ 397 million in 2023 and is forecast to a readjusted size of US$ 600 million by 2030 with a CAGR of 6.5% during the forecast period 2024-2030.
Published: 2024-12-12
Pages: 96
USD 3950.00 (Single User License)Global Canine Tumor Screening Market Insights, Forecast to 2030
Valued at US$ 411 million in 2024, the global Canine Tumor Screening market is forecast to reach US$ 600 million by 2030, at a CAGR of 6.5% during the forecast period.
Published: 2024-12-12
Pages: 128
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now